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Purpose:  
Pancreatic cancer was the fourth leading cause of death from cancer in the United 
States in 2010 and the fifth leading cause of death from cancer in Japan, and its 
incidence is still increasing. Dendritic cell (DC)-based cancer vaccine may hold 
significant impact on the survival of advanced pancreatic cancers; however, multiple 
variations among clinical studies, i.e. quality of cells, make it hard to detect its clinical 
benefit. We therefore statistically identified factors determining the clinical benefit 
from data of seven Japanese individual institutions that share the same DC preparation 
and treatment regimen. 
Patients and Methods:  
Among 354 patients who met inclusion criteria, 255 cases who received standard 
chemotherapy combined with peptide-pulsed DC vaccine were analyzed.  
Results:   
Mean survival time from diagnosis was 16.5 months (95%C.I.=14.4-18.5), and that from 
the first vaccination was 9.9 months (95%C.I.=8.0-12.9). Known prognostic ‘baseline’ 
factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, 
liver metastasis, and prognostic nutrition index (PNI) were also representative in this 
study. Importantly, erythema reaction after vaccination was an independent and 
treatment-related predictive factor for better survival. Adjuvant use of OK432 might be 
important to show erythema reaction. 
Conclusion:  
This is the first to report a multicenter clinical study, suggesting the feasibility and 
possible clinical benefit of add-on DC vaccine on the patients with advanced pancreatic 
cancer who are undergoing chemotherapy. These findings seem reasonable and 
encouraging; however, because of the retrospective and exploratory nature of the 
present study, these findings need to be addressed in well-controlled prospective 
randomized trials. 
